Please login to the form below

niraparib

This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.

Pfizer takeover rumour ignites Amarin shares

GlaxoSmithKline paid $5.1bn for Tesaro and its PARP inhibitor Zejula (niraparib) last month, and Eli Lilly snapping up Loxo Oncology for $8bn to claim its just-approved Vikrakvi (larotrectinib) for

Latest news

First-line ovarian approval cements AZ’s Lynparza lead

Lynparza is already well in front of its PARP inhibitor rivals, Tesaro’s Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib).
Analysts lukewarm on GSK’s new cancer acquisition

That includes the marketed PARP inhibitor Zejula (niraparib) that it says is in a market with “very favourable growth prospects,” albeit with strong competition from AstraZeneca and Merck/MSD’s
GSK buys cancer firm Tesaro for $5.1bn

of the year – gives GSK rights to approved PARP inhibitor Zejula (niraparib), which is jostling for market share with AstraZeneca's Lynparza (olaparib) and Clovis Oncology's Rubraca (rucaparib).
AZ and Clovis PARP inhibitors show their mettle at ESMO

extend its lead over its PARP inhibitor rivals, Tesaro's Zejula (niraparib) and Clovis' Rubraca (rucaparib).
AZ's Lynparza closes in on first line ovarian cancer use

Tesaro is also expecting phase III results in the same setting for its PARP inhibitor Zejula (niraparib), but that data won’t be available until next year.

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest Intelligence

Deal Watch April 2016

Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer

The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer. ... The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Senior Account Director development role to Business Director, H...: Excellent package

Account Director – Healthcare Marketing – Berks: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Manager / Account Director: Competative

Medical Writer: Salary TBC

Associate Director: £75, 000-90, 000

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Senior Account Manager: Competitive Salary Offered

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Director: Competitive Salary Offered

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Manager / Senior Account Manager: 35, 000-40, 000

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Business Director: Competitive Salary Offered

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Director, Healthcare Marketing Agency: Salary TBC

Global Business Development Director – Health Education: excellent commission

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....